Study of Certain Biomarkers in Iraqi Female Patients with Breast Cancer

Main Article Content

Abeer M. Hussain
Ali Hussein Mohammed AL-Khafaji
Alia Hussain Ali
Haider Latif Mohammed


The prospective study has been designed to determine some biomarkers in Iraqi female patients with
breast cancer. The current study contained 30 patients whose tissue samples have been collected from
hospitals in Medical City in Baghdad after consent patients themselves and used immunohistochemical
technique to determine these markers. The results showed a significant correlation between ER and PR tissue
markers (Sig = 0.000) and a significant correlation between cyclin E phenotype and cyclin E intensity (Sig =


Download data is not yet available.

Article Details

How to Cite
Hussain AM, Mohammed AL-Khafaji AH, Ali AH, Mohammed HL. Study of Certain Biomarkers in Iraqi Female Patients with Breast Cancer. Baghdad Sci.J [Internet]. 2021Dec.1 [cited 2021Dec.4];18(4):1140. Available from:


AICR American Institute of Cancer Research. Diet,

Nutrition, Physical activity and breast cancer. World

Cancer Research Fund. 2017 .Pp: 4.

Martínez-Montiel N, Anaya-Ruiz M, Pérez-Santos

M, Martínez-Contreras RD. Alternative Splicing in

Breast Cancer and the Potential Development of

Therapeutic Tools. Genes. 2017; 8 (217): 1 – 14.

Available from

DOI: 10.3390/genes8100217.

ACS American Cancer Society. Cancer Facts and

Figures2018. Atlanta. American Cancer

Society.Inc.Pp: 1, 12.

Saifullah PH, AL-Kazzaz FF, Zayzafoon NN.

Study of Malondialdehyde levels in sera, RBCs ant

tissues homogenate of Iraqi women with breast

tumors. Baghdad Sci J. 2009; 6 ( 3 ) : 553 – 562 .

Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini

A, Senkus E, et al. Clinical use of biomarkers in

breast cancer: Updated guidelines from the European

Group on Tumor Markers (EGTM) .Eur J of Cancer.

; 75: 284e – 298e. Available from http:// DOI: 10.1016/j.ejca.2017.01.017.

Open Access Baghdad Science Journal P-ISSN: 2078-8665

, 18(4): 1140-1148 E-ISSN: 2411-7986

Weigel MT, Dowsett M. Current and emerging

biomarkers in breast cancer: prognosis and prediction

. EndocrRelat Cancer. 2010; 17 (1): R245 – R262.

Available fromhttp://www.endocrinology- 10.1677/ERC-10-0136.

Bjornstrom L, Sjoberg M . Mechanisms of Estrogen

Receptor Signaling: Convergence of Genomic and

Nongenomic Actions on Target Genes

.MolEndocrinol. 2005; 19 (4): 833 – 842. Available


abstract/19/4/833/2741274.DOI: 10.1210/me.2004-

Yue W, Wang J-P, Li Y, Fan P, Liu G, Zhang

N, et al. Effects of estrogen on breast cancer

development: role of estrogen receptor independent

mechanisms. Int J Cancer. 2010; 127 (8): 1748

–1757. DOI: 10.1002/ijc.25207.

Micheli A, Muti P, Secreto G, Krogh V, Meneghini

E, Venturelli E, et al. Endogenous sex hormones

and subsequent breast cancer in premenopausal

women.Int.J Cancer. 2004; 112 (1):312 – 318

.Available from


Majumder A, Singh M, Tyagi SC. Post-

menopausal breast cancer: from estrogen to androgen

receptor .Oncotarget. 2017; 8 (60): 102739 – 102758.

Selli C, Sims AH.Neoadjuvant Therapy for Breast

Cancer as a Model for Translational Research . Breast

Cancer: Basic and Clin Res. 2019; 13: 1- 7. DOI:


Wang J, Xu B. Targeted therapeutic options and

future perspectives for HER2-positive breast cancer

.Signal Transduct Target Ther. 2019; 4 ( 34 ) : 1 –

Available from http: // doi. Org DOI:


Sareyeldin RM, Gupta I, Al-Hashimi I, Al-

Thawadi HA, Al Farsi HF, Vranic S, et al. Gene

Expression and miRNAs Profiling: Function and

Regulation in Human Epidermal Growth Factor

Receptor 2 (HER2)-Positive Breast Cancer. Cancers.

; 11 (646): 1 – 20. Available from

3390/cancers 11050646.

Furrer D, Paquet C, Jacob S, Diorio C. The

Human Epidermal Growth Factor Receptor 2 ( HER2

) as a prognostic and predictive biomarker: molecular

insights into HER2 activation and diagnostic

implications. IntechOpe. 2018; 11 – 31.Available

from http : // DOI:


Wilson FR, Coombes ME, Wylie Q, Yurchenko

M, Brezden-MasleyCh, Hutton B, et al. Herceptin

(trastuzumab) in HER2-positive early breast cancer:

protocol for a systematic review and cumulative

network meta-analysis. Systematic Reviews. 2017; 6

(196): 1 – 8. Available from


Mokuyasu S, Suzuki Y.Clinical Utility of Serum

Human Epidermal Growth Factor Receptor Type 2

Testing as a Marker of Therapeutic Response in

Tissue HER2-Positive Breast Cancer Patients . Int J

Cancer Clin Res. 2017; 4 ( 2 ) : 1 – 6. DOI:


Cianfrocca M, Goldstein LJ. Prognostic and

Predictive Factors in Early-Stage Breast Cancer.

Oncologist. 2004; 9 : 606 – 616 .

Hatem SF, Alyaqubi KJ, Al-Atrooshi SAB – W,

Alsayyid MM, Saad M, Safaa R. The Study of

HER-2/neu, ER/PR Expression Using

Immunohistochemistry (IHC) in the Iraqi Breast

Cancer.Kufa J For Veter Med Sci .2016; 7 ( 1 ): 18 –


Chappuis PO, Donato E, Goffin JR, Wong N,

Be´gin LR, Kapusta LR, et al. Cyclin E expression

in breast cancer: predicting germline BRCA1

mutations, prognosis and response to treatment.

Annals of Oncology.2005; 16: 735 –




Hwang HC, Clurman BE. Cyclin E in normal and

neoplastic cell cycles.Oncogene.2005; 24: 2776 –

DOI: 10.1038/sj.onc.1208613.

Law ME, Corsino PE, Narayan S, Law BK.

Cyclin-Dependent Kinase Inhibitors as Anticancer

Therapeutics.Mol.Pharmacol.2015; 88: 846 –

Available from http:// DOI:


Akli S, Carolyn S, Pelt V, Bui T, Multani AS,

Chang S, et al. Overexpression of the Low Molecular

Weight Cyclin E in Transgenic Mice Induces

Metastatic Mammary Carcinomas through the

Disruption of the ARF-p53 Pathway . Cancer Res .

; 67: (15) : 7212 – 7222 . Available from : 10.1158/0008-

CAN-07-0599 .

Karakas C, Biernacka A, Bui T, Sahin AA, Yi M,

Akli S, et al.CytoplasmicCyclin E and Phospho-

Cyclin - Dependent Kinase 2 Are Biomarkers of

Aggressive Breast Cancer. The Am J of Pathol. 2016;

(7): 1900 – 1912. Available from http:// DOI: 10.1016/j.ajpath.2016.02.024 .

Duronio RJ, Xiong Y. Signaling pathways that

control cell proliferation. Cold Spring Harbor

perspectives in biology. 2013 Mar

;5(3):a008904.Available from


Iqbal BM, Buch A. Hormone receptor (ER, PR,

HER2/neu) status and proliferation index marker (Ki-

in breast cancers: Their onco-pathological

correlation, shortcomings and future trends. Med J

DYPatil Univ. 2016; 9 (6): 674 – 679.Available


/194180. DOI: 10.4103/0975-2870.194180.

Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi

M, Sahin AA, et al. Cytoplasmic Cyclin E Predicts

Recurrence in Patients with Breast Cancer. Clin

Cancer Res. 2016; 0f1 – of12.Available from 10.1158/1078-


Open Access Baghdad Science Journal P-ISSN: 2078-8665

, 18(4): 1140-1148 E-ISSN: 2411-7986

Nuttall FQ.Body Mass Index Obesity, BMI, and

Health: A Critical Review. Nutr Today. 2015; 50 (3):

– 128. Available from


Mahir W, Rouas L, Ouzir M, Ferhati D, Rhrab

B, Alhamany Z, Cherradi N. Correlation of ER, PR

and HER2 with clinico-pathological parameters in

Infiltrating Ductal Carcinoma of Breast in Morocco

.Int J of Innovation and Applied Studies.2016; 14 (2)

: 498 – 506.

Arafah M. Correlation of Hormone Receptors with

Her-2 Neu Protein Expression and the Histological

Grade in Invasive Breast Cancers in a Cohort of

Saudi Arabia.Turkish J of Pathol. 2012; 28 (1): 38 –

Available from http://www.endocrinology- 10.5146/tjpath.2012.01095.

Horwitz KB, McGuire WL.Estrogen control of

progesterone receptor in human breast cancer

correlation with nuclear processing of estrogen

receptor. The J ofbiol Chem. 1978; 253 (7): 2223 –

Dubowy RL, Feinberg RF, Keefe DL, Doncel

GF, Williams ShC, McSweet JC, et al . Improved

endometrial assessment using cyclin E and p27.

Fertility and Sterility.2003; 80 (1): 146 – 156. DOI: